课题基金 / 基金详情

ABI PRISM 7700 SEQUENCE DETECTION SYSTEM

ABI PRISM 7700 SEQUENCE DETECTION SYSTEM
ABI PRISM 7700 序列检测系统
批准号:
6292203
负责人:
William Borkowsky
金额:
$8.77万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-01 至 2002-07-31

项目摘要

项目成果

William Borkowsky的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(调查员?摘要):实时PCR已经导致了 准确和定量测量核酸的能力, 灵敏度这可以通过1)使用TAQMAN技术来实现, 利用TAQ酶的核酸外切酶活性,允许表达, 在每个PCR循环中可检测到的荧光信号的测量 扩增和2)分子信标技术,一种其中 荧光分子和猝灭剂在结合到 互补扩增子也在扩增期间产生并测量荧光信号。 每个PCR扩增。ABI PRISM 7700分子序列检测仪, TAQMAN升级包具有使用这些技术的能力。它有 同时测量4个单独的荧光信号的能力, 同样的反应。这种仪器也被用来检测遗传 使用适当设计的分子信标的多态性。各种 纽约大学的调查人员已经熟悉了 并期望获得文书将提高他们的能力 进行对其当前或预期研究至关重要的测量。的 仪器将成为科学家个人使用的共享资源 整个医学院。没有类似的文书, 整个医学院目前。它也将被纽约大学中心利用 艾滋病研究(CFAR)核心病毒学实验室(由Borkowsky博士指导), 作为一个主机的调查人员从事艾滋病研究和纽约大学一般 临床研究中心(GCRC),为纽约大学研究者社区提供服务 从事临床研究。仪器的使用将由 代表CFAR和GCRC的内部咨询小组。的运行成本 通过仅收取试剂成本和仪器费用, 维护,并将由GCRC和个人的资金补贴 赠款。首席研究员将负责帮助设计 引物和探针,并确保测定和 负责管理的人员必须经过适当的质量控制程序。
英文摘要
DESCRIPTION: (Investigator?s Abstract): Real-Time PCR has resulted in the ability to accurately and quantitatively measure nucleic acid with great sensitivity. This can be accomplished by 1) using TAQMAN technology which, using the exonuclease activity of TAQ enzyme, allows for the expression and measurement of a fluorescent signal that can be detected at each cycle of PCR amplification and 2) Molecular Beacon technology, a technique in which unfolding of a fluorescent molecule and quencher after binding to a complementary amplicon, also generates and measures a fluorescent signal during each PCR amplification. The ABI PRISM 7700 molecular sequence detector with a TAQMAN upgrade package has the capability of using these technologies. It has the capability of measuring 4 separate fluorescent signals simultaneously in the same reaction. This instrument has also been used to detect genetic polymorphisms using appropriately designed molecular beacons. Various investigators throughout NYU are already familiar with the power of the instrument and expect that access to the instrument will improve their ability to perform measurements crucial to their current or expected research. The instrument will be a shared resource utilized by individual scientists throughout the medical school. There is no comparable instrument within the entire medical school at present. It will be also utilized by the NYU Center for AIDS Research (CFAR) Core Virology Lab (directed by Dr. Borkowsky) which serves as a host of investigators engaged in AIDS Research and the NYU General Clinical Research Center (GCRC) which serves the NYU community of investigators engaged in clinical research. Usage of the instrument will be monitored by an internal advisory group representing the CFAR and GCRC. The cost of running assays will be minimized by charging only for reagent cost and instrument maintenance and will be subsidized by funds from the GCRC and from individual grants. The principal investigator will be responsible for helping design primers and probes for the instrument as well as insure that the assay and those who manage it undergo appropriate quality control procedures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Virology Core
CLINICAL TRIAL: PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRAT
CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC
CLINICAL TRIAL: PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)
海外基金